跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Fiasp - Philippines FDA Drug Approval Details
Approvals
/
Philippines FDA
/
Fiasp
Approved
STANDARD
Fiasp
Novo Nordisk Pharmaceutical Industries, LP
🇵🇭 Food and Drug Administration - Philippines
Approval Date
Jul 14, 2025
Approval ID
f026ccafb44100ff
Company
Novo Nordisk Pharmaceutical Industries, LP
Type
Standard
Approval Details
Approval Id
f026ccafb44100ff
Drug Approval Philippines Name
Fiasp
Product Name
Fiasp
Registration Number
BR-1406
Brand Name
Fiasp
Generic Name
Insulin Aspart
Dosage Form
Solution for Injection (IV/SC)
Dosage Strength
100 Units (equivalent to 3.5 mg)/mL
Manufacturer
Novo Nordisk Pharmaceutical Industries, LP
Importer
Novo Nordisk Pharmaceuticals (Philippines), Inc.
Distributor
Novo Nordisk Pharmaceuticals (Philippines), Inc.
Company Detail Path
/organization/novo-nordisk-pharmaceutical-industries-lp
Issuance Date
14 July 2022
Expiry Date
14 July 2027
Pharmacologic Category
Antidiabetics
Classification
Prescription Drug (RX)
Active Ingredients
Approved
Quick Info
Agency
Philippines FDA
Country
🇵🇭
Approval Date
Jul 14, 2025
Approval ID
f026ccafb44100ff
Type
Standard
Back to Philippines FDA Approvals